Advanced Colorectal Cancer

Oncology·MeSH: Colorectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

15 drugs in development·7 companies·7 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
leucovorin calcium preservative free	Seagen Inc. (SGEN)
leucovorin calcium preservative free	Mylan II B.V. (MYL)

Phase 3(5)

Drug	Company
Amivantamab + FOLFIRI	IGM Biosciences, Inc. (IGMS)
Cetuximab	ENANTA PHARMACEUTICALS INC (ENTA)
folfiri regimen	Mirati Therapeutics, Inc. (MRTX)
folfox	GH Research PLC (GHRS)
mfolfox6 regimen	Mirati Therapeutics, Inc. (MRTX)

Phase 2(5)

Drug	Company
Amivantamab	IGM Biosciences, Inc. (IGMS)
Amivantamab IV	IGM Biosciences, Inc. (IGMS)
Avutometinib	ENANTA PHARMACEUTICALS INC (ENTA)
Defactinib	ENANTA PHARMACEUTICALS INC (ENTA)
folinic acid	AbbVie Inc. (ABBV)

Phase 1(2)

Drug	Company
mrtx849	Mirati Therapeutics, Inc. (MRTX)
ProAgio	IGM Biosciences, Inc. (IGMS)

Phase 1/Phase 2(1)

Drug	Company
cetuximab	Mirati Therapeutics, Inc. (MRTX)

BioSniper tracks 15 drugs in development for Advanced Colorectal Cancer across 7 companies.

There are 7 clinical trials targeting Advanced Colorectal Cancer tracked by BioSniper.

The estimated prevalence of Advanced Colorectal Cancer is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.